The elimination of hepatitis D as a public health problem : Needs and challenges
© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd..
Infection with hepatitis D virus leads to liver disease and cancer most rapidly of all hepatitis viruses. However, knowledge about hepatitis D remains poor and the burden and impact are underestimated, even though some 12-15 million people mainly in low- and middle-income countries may be affected. Its epidemiology is changing, with increasing migration leading to increased risks of infection and disease. A recent Viral Hepatitis Prevention Board meeting reviewed the current epidemiological status, improvements in diagnostic testing, advances in the development of novel antiviral agents in phase III trials and the need for a greater public health response, such as new guidelines and recommended testing of all people newly identified as infected with hepatitis B virus for hepatitis D virus infection. It identified issues and needs for attention with regard to prevention, diagnosis and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 31(2024), 1 vom: 03. Jan., Seite 47-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vanwolleghem, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 28.12.2023 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.13891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362834776 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362834776 | ||
| 003 | DE-627 | ||
| 005 | 20240426233317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM362834776 | ||
| 035 | |a (NLM)37789715 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vanwolleghem, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The elimination of hepatitis D as a public health problem |b Needs and challenges |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.12.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd. | ||
| 520 | |a Infection with hepatitis D virus leads to liver disease and cancer most rapidly of all hepatitis viruses. However, knowledge about hepatitis D remains poor and the burden and impact are underestimated, even though some 12-15 million people mainly in low- and middle-income countries may be affected. Its epidemiology is changing, with increasing migration leading to increased risks of infection and disease. A recent Viral Hepatitis Prevention Board meeting reviewed the current epidemiological status, improvements in diagnostic testing, advances in the development of novel antiviral agents in phase III trials and the need for a greater public health response, such as new guidelines and recommended testing of all people newly identified as infected with hepatitis B virus for hepatitis D virus infection. It identified issues and needs for attention with regard to prevention, diagnosis and treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a hepatitis D virus (HDV) | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Armstrong, Paige A |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a FitzSimons, David |e verfasserin |4 aut | |
| 700 | 1 | |a Valckx, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Hendrickx, Greet |e verfasserin |4 aut | |
| 700 | 1 | |a Van Damme, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 31(2024), 1 vom: 03. Jan., Seite 47-50 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:47-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 1 |b 03 |c 01 |h 47-50 | ||